Skip to content
Lanreotide
Somatuline Depot (lanreotide) is a protein pharmaceutical. Lanreotide was first approved as Somatuline depot on 2007-08-30. It is used to treat acromegaly and neuroendocrine tumors in the USA. The pharmaceutical is active against somatostatin receptor type 2 and somatostatin receptor type 5. In addition, it is known to target somatostatin receptor type 3.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
musculoskeletal diseasesD009140
nervous system diseasesD009422
endocrine system diseasesD004700
Trade Name
FDA
EMA
Somatuline depot
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lanreotide acetate
Tradename
Company
Number
Date
Products
LANREOTIDE ACETATECiplaN-215395 RX2021-12-17
3 products, RLD, RS
SOMATULINE DEPOTIpsenN-022074 RX2007-08-30
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
somatuline depotNew Drug Application2019-09-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acromegalyD000172
neuroendocrine tumorsEFO_1001901D018358D3A.8
Agency Specific
FDA
EMA
Expiration
Code
LANREOTIDE ACETATE, SOMATULINE DEPOT, IPSEN PHARMA
2024-09-15ODE-156
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
H01: Pituitary and hypothalamic hormones and analogues
H01C: Hypothalamic hormones
H01CB: Somatostatin and analogues
H01CB03: Lanreotide
HCPCS
Code
Description
J1930
Injection, lanreotide, 1 mg
Clinical
Clinical Trials
309 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HygieneD006920140445
Septic shockD012772A48.31211013
SepsisD018805A41.91157
HypotensionD007022EFO_0005251I9511135
BurnsD002056T30.01113
Wounds and injuriesD014947T14.8123
PsoriasisD011565EFO_0000676L40213
Bacterial vaginosisD016585EFO_00039321113
Atopic dermatitisD003876EFO_0000274L20123
PneumoniaD011014EFO_0003106J18112
Show 26 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients17412
HyperlactatemiaD065906167
Macular degenerationD008268EFO_0001365H35.30527
NeoplasmsD009369C802215
Traumatic brain injuriesD000070642S062225
ShockD012769R57.12124
PancreatitisD010195EFO_0000278K851123
Cardiopulmonary bypassD002315123
Subarachnoid hemorrhageD013345EFO_0000713I60123
Hemorrhagic shockD0127711113
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25213
Non-small-cell lung carcinomaD002289212
Prostatic neoplasmsD011471C6122
Systemic sclerodermaD012595EFO_0000717M3422
Heart arrestD006323EFO_0009492I46112
Macular edemaD008269111
Retinal vein occlusionD012170EFO_1001157H34.81111
Diabetic retinopathyD003930EFO_000377011
StrokeD020521EFO_0000712I63.911
Intraoperative complicationsD00743111
Show 15 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic ductal carcinomaD02144111
Striae distensaeD057896HP_0001065L90.611
Type 2 diabetes mellitusD003924EFO_0001360E1111
Dental cariesD003731EFO_0003819K0211
Multiple myelomaD009101C90.011
ObesityD009765EFO_0001073E66.911
Prediabetic stateD011236EFO_1001121R73.0311
Insulin resistanceD007333EFO_000261411
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
HyperinsulinismD006946HP_0000842E16.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cesarean sectionD00258555
Acute kidney injuryD058186HP_0001919N1733
InflammationD00724933
Critical illnessD01663822
SeizuresD012640G40.422
MortalityD009026EFO_000435222
Postoperative complicationsD01118322
Craniofacial abnormalitiesD01946522
ArthrogryposisD001176EFO_0003857Q74.322
Infectious arthritisD001170EFO_1001351M0022
Show 63 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLANREOTIDE
INNlanreotide
Description
LANREOTIDE
Classification
Peptide
Drug classpeptides: inhibition of growth hormone release
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O
Identifiers
PDB
CAS-ID108736-35-2
RxCUI68092
ChEMBL IDCHEMBL1201185
ChEBI ID
PubChem CID6918011
DrugBankDB06791
UNII ID0G3DE8943Y (ChemIDplus, GSRS)
Target
Agency Approved
SSTR2
SSTR2
SSTR5
SSTR5
Organism
Homo sapiens
Gene name
SSTR2
Gene synonyms
NCBI Gene ID
Protein name
somatostatin receptor type 2
Protein synonyms
SRIF-1, SS2R
Uniprot ID
Mouse ortholog
Sstr2 (20606)
somatostatin receptor type 2 (Q91Y73)
Alternate
SSTR3
SSTR3
Organism
Homo sapiens
Gene name
SSTR3
Gene synonyms
NCBI Gene ID
Protein name
somatostatin receptor type 3
Protein synonyms
SSR-28
Uniprot ID
Mouse ortholog
Sstr3 (20607)
somatostatin receptor type 3 (Q3UVV5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,929 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
217 adverse events reported
View more details